acute lymphoblastic leukaemia
ViroCell and UCL launch trial to treat childhood leukaemia relapse
April 24, 2025Research and Development Oncology, UCL, ViroCell, acute lymphoblastic leukaemia, cell therapy, clinical trial, leukaemia
ViroCell Biologics has manufactured a GMP-grade lentiviral vector for a University College London (UCL) clinical trial aimed at tackling relapse …
Qlucore and Sahlgrenska Hospital sign agreement for ALL diagnosis software
January 17, 2024Business Services Oncology, Qlucore, Sahlgrenska Hospital, acute lymphoblastic leukaemia, leukaemia
Qlucore has announced that it has entered into an agreement with Sahlgrenska Hospital, in Gothenberg, Sweden. This agreement means the …
Sanofi acquires biotech firm Synthorx for $2.5 billion
December 9, 2019Sales and Marketing Genetic Alphabet, Sanofi, acute lymphoblastic leukaemia, leukaemia
Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion). Paul Hudson, …
NICE recommends Amgen’s Blincyto in rare acute lymphoblastic leukaemia sub-population
June 19, 2019Research and Development, Sales and Marketing Amgen, Cancer, NICE, acute lymphoblastic leukaemia, blincyto, pharma
Patients on the NHS in England and Wales will now be able to access Amgen’s Blincyto (blinatumomab) after NICE reveals …
Patient deaths lead Juno Therapeutics to halt trial for second time
November 24, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acute lymphoblastic leukaemia, clinical trial deaths, juno therapeutics
Juno Therapeutics has been forced to halt a trial investigating the efficacy of its lead experimental CAR-T cancer treatment JCAR015 …
Pfizer’s leukaemia drug beats chemotherapy in Phase III trials
June 13, 2016Research and Development, Sales and Marketing Inotuzumab ozogamicin, Pfizer, acute lymphoblastic leukaemia
Pfizer (NYSE: PFE) has announced data from a pivotal Phase III trial for acute lymphoblastic leukaemia (ALL) drug, inotuzumab ozogamicin, …
